Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Organofluorides Stories

2013-12-15 23:01:57

The Firm is now investigating Lipitor lawsuits on behalf of individuals who developed new-onset Type 2 diabetes, allegedly due to their use of the cholesterol-lowering statin. New York, New York (PRWEB) December 15, 2013 A new Lipitor lawsuit (http://www.thelipitorlawsuit.com/) filed in Kentucky claims that a woman’s Type 2 diabetes could have been avoided were it not for allegedly inadequate warnings provided by Pfizer, Inc., Bernstein Liebhard LLP reports. The complaint, which was...

2013-12-14 23:01:57

The firm is currently offering Risperdal lawsuit evaluations to those who allege that they suffered from the drug’s alleged side effects. (PRWEB) December 14, 2013 Risperdal plaintiffs have asked a Pennsylvania judge to unseal clinical studies data, citing its importance to the public interest, according to court documents. The Rottenstein Law Group LLP, which represents clients in Risperdal lawsuits, notes that the documents detail potential risks associated with the antipsychotic...

2013-12-13 08:24:48

VENTANA HER2 (4B5) IHC assay label expansion coincides with therapy availability in many non-U.S. countries globally TUCSON, Ariz., Dec. 13, 2013 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, today announces the VENTANA HER2/neu (4B5) Rabbit Monoclonal Primary Antibody assay as a companion diagnostic(1) for detecting HER2 protein expression for patients who, in countries where they are approved, may be appropriate candidates for Perjeta(®) (pertuzumab)...

2013-12-12 23:28:53

Rapid CYP2C19 Testing for Heart Attack Patients Using Antiplatelet Drugs in 150-Patient Clinical Trial With Spartan Bioscience Ottawa, Ontario (PRWEB) December 12, 2013 Spartan Bioscience today announced the start of a 150-patient study of personalized medicine for cardiac stent patients in Poland, Hungary, and Lithuania. The study is sponsored by the Medical University of Warsaw, and is entitled “Bedside Genetic or Pharmacodynamic Testing to Prevent Periprocedural Myonecrosis During...

2013-12-12 23:00:57

Bernstein Liebhard LLP is evaluating Risperdal lawsuits on behalf of young men and boys who developed gynecomastia, or male breast growth, allegedly due to their use of the antipsychotic drug. New York, New York (PRWEB) December 12, 2013 Risperdal lawsuits (http://www.risperdallawsuitcenter.com/) , including many that allege use of the antipsychotic drug caused some men and young boys to develop gynecomastia, or male breast growth, continue to move forward in a consolidated litigation...

2013-12-12 20:24:59

ZURICH, December 12, 2013 /PRNewswire/ -- - First Head to Head Study Showed Tecta(R) As Effective for Healing and Complete Remission of Erosive GERD with Significantly Higher Symptom Relief After 8 Weeks compared to Esomeprazole[1] - Takeda Pharmaceuticals International GmbH (Takeda) announced today results showing pantoprazole magnesium 40 mg (Tecta(R)) was as effective as esomeprazole 40 mg for achieving complete remission...

2013-12-12 12:27:19

NSCLC Treatment Will Become Increasingly Personalized Due to Emergence of Novel Targeted Therapies with Companion Diagnostic Tests, According to Findings from Decision Resources BURLINGTON, Mass., Dec. 12, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the entry of twelve new therapies into the non-small-cell lung cancer (NSCLC) drug market will drive the market's growth from $4.9...

2013-12-11 23:02:43

The Latest Risperdal Lawsuits Show That Johnson & Johnson's Request to Keep Risperdal Studies Sealed Follows Announcement of $2.2 Billion Settlement with Federal Government to Resolve Criminal, Civil Charges Involving Off-Label Marketing of Risperdal, Other Medications. (PRWEB) December 11, 2013 Wright & Schulte LLC has learned that Johnson & Johnson has filed a motion in Risperdal lawsuits pending in Pennsylvania state court to keep sealed certain clinical studies...

2013-12-11 12:23:44

The Acute Hospital Market Will See a Decline in Sales Through 2022 Due to Genericization of Expensive Agents, According to a New Report from Decision Resources BURLINGTON, Mass., Dec. 11, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the launch of numerous add-on therapies in the acute coronary syndrome (ACS) 12-month posthospital setting will result in market growth from $1.7...

2013-12-10 12:27:28

Entry of 11 New High-Value Branded Agents and a Growing NSCLC Population Will Drive Market Growth, According to a New Report from Decision Resources BURLINGTON, Mass., Dec. 10, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that, from 2013 to 2018, the non-small-cell lung cancer (NSCLC) market in Argentina, Brazil and Mexico will increase at an annual rate of six percent, reaching...